Top
image credit: Adobe Stock

GSK and Vir Biotech amend COVID-19 research partnership

February 16, 2023

Via: PMLiVE

The companies will still continue to work together on their SARS-CoV-2-targeting antibody, sotrovimab, in markets where it is authorised, as well as their experimental COVID-19 antibody, VIR-7832, and a portfolio of other therapies for respiratory diseases such as influenza.

Originally agreed in April 2020, the collaboration saw the two partners use Vir’s monoclonal antibody platform technology to accelerate research of existing antiviral antibodies and identify new antiviral antibodies that could be developed as therapeutic or preventive options for COVID-19.

Read More on PMLiVE